Role of dihydroxyvitamin D3 and its nuclear receptor in novel directed therapies for cancer

General Physiology and Biophysics

Volumn 25, Issue 4, 2006, Pages 339-353

  Ondkova S ^a   Macejova D ^a   Brtko, Július ^a  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

9 cis retinoic acid; Cancer therapy; Dihydroxyvitamin D3; Metabolism; Nuclear receptor

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYERGOCALCIFEROL; ALITRETINOIN; CALCITRIOL; CELL NUCLEUS RECEPTOR; COLECALCIFEROL; DIHYDROXYCOLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; HETERODIMER; ISOTRETINOIN; RETINOIC ACID RECEPTOR; SITOSTEROL; STIGMASTEROL; VITAMIN D RECEPTOR;

CANCER; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; DRUG RESEARCH; DRUG TARGETING; ENDOCRINOLOGY; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OVARY CANCER; PROTEIN FUNCTION; SHORT SURVEY;

24,25-DIHYDROXYVITAMIN D 3; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 33947269164     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (99)

1. Abe-Hashimoto J., Kikuchi T., Matsumoto T., Nishii Y., Ogata E., Ikeda K. (1993): Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res. 53, 2534-2537
2. Albertson D. G., Ylstra B., Segraves R., Collins C., Dairkee S. H., Kowbel D., Kuo W. L., Gray J. W., Pinkel D. (2000): Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25, 144-146
3. Anderson M. G., Nakane M., Ruan X., Kroeger P. E., Wu-Wong J. R. (2006): Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57, 234-240
4. Axen E., Postlind H., Sjoberg H., Wikvall K. (1994): Liver mitochondrial cytochrome P450 CYP27 and recombinant-expressed human CYP27 catalyze 1α-hydroxylation of 25-hydroxyvitamin D3. Proc. Natl. Acad. Sci. U.S.A. 91, 10014-10018
5. Baker A. R., McDonnell D. P., Hughes M., Crisp T. M., Mangelsdorf D. J., Haussler M. R., Pike J. W., Shine J., O'Malley B. W. (1988): Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci. U.S.A. 85, 3294-3298
6. Bareis P., Bises G., Bischof M. G., Cross H. S., Peterlik M. (2001): 25-hydroxyvitamin D metabolism in human colon cancer cells during tumor progression. Biochem. Biophys. Res. Commun. 285, 1012-1017
7. Barreto A. M., Schwartz G. G., Woodruff R., Cramer S. D. (2000): 25-hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 9, 265-270
8. Bello D., Webber M. M., Kleinman H. K., Wartinger D. D., Rhim J. S. (1997): Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18, 1215-1223
9. Bises G., Kallay E., Weiland T., Wrba F., Wenzl E., Bonner E., Kriwanek S., Obrist P., Cross H. S. (2004): 25-hydroxyvitamin D3-1a-hydroxylase expression in normal and malignant human colon. J. Histochem. Cytochem. 52, 985-989
10. Bischof M. G., Siu-Caldera M. L., Weiskopf A., Vouros P., Cross H. S., Peterlik M., Reddy G. S. (1998): Differentiation-related pathways of 1a,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1α,25-dihydroxy-3epi-cholecalciferol. Exp. Cell Res. 241, 194-201
11. Bizzarri M., Cucina A., Valente M. G., Tagliaferri F., Borrelli V., Stipa F., Cavallaro A. (2003): Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures. J. Surg. Res. 110, 332-337
12. Blutt S. E., Weigel N. L. (1999): Vitamin D and prostate cancer. Proc. Soc. Exp. Biol. Med. 221, 89-98
13. Bortman P., Folgueira M. A., Katayama M. L., Snitcovsky I. M., Brentani M. M. (2002): Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz. J. Med. Biol. Res. 35, 1-9
14. Bostwick D. G. (1995): High grade prostatic intraepithelial neoplasia. Cancer 75, 1823-1836
15. Brenza H. L., DeLuca H. F. (2000): Regulation of 25-hydroxyvitamin D3 1α-hydroxylase gene expression by parathyroid hormone and 1,25-dihydroxyvitamin D3. Arch. Biochem. Biophys. 381, 143-152
16. Brtko J., Thalhamer J. (2003): Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr. Pharm. Des. 9, 2067-2077
17. Campbell-Thompson M., Lynch I. J., Bhardwaj B. (2001): Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res. 61, 632-640
18. Carlberg C. (1995): Mechanisms of nuclear signalling by vitamin D3. Interplay with retinoid and thyroid hormone signalling. Eur. J. Biochem. 231, 517-527
19. Carlberg C. (2003): Molecular basis of the selective activity of vitamin D analogues. J. Cell. Biochem. 88, 274-281
20. Colston K. W., Berger U., Wilson P., Hadcocks L., Naeem I., Earl H. M., Coombes R. C. (1988): Mammary gland 1,25-dihydroxyvitamin D3 receptor content during pregnancy and lactation. Mol. Cell. Endocrinol. 60, 15-22
21. Cross H. S., Peterlik M., Reddy G. S., Schuster I. (1997): Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1α-hydroxylase activity and regulation of side-chain metabolism. J. Steroid Biochem. Mol. Biol. 62, 21-28
22. 3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287-292
23. Darwish H. M., DeLuca H. F. (1996): Recent advances in the molecular biology of vitamin D action. Prog. Nucleic Acid Res. Mol. Biol. 53, 321-344
24. Dusso A. S., Brown A. J., Slatopolsky E. (2005): Vitamin D. Am. J. Physiol. Renal. Physiol. 289, F8-28
25. Evans R. M. (1988): The steroid and thyroid hormone receptor superfamily. Science 240, 889-895
26. Faraco J. H., Morrison N. A., Baker A., Shine J., Frossard P. M. (1989): Apal dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res. 17, 2150-2159
27. Feldman D. (1997): Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J. Natl. Cancer Inst. 89, 109-111
28. Feldman D., Skowronski R. J., Peehl D. M. (1995): Vitamin D and prostate cancer. Adv. Exp. Med. Biol. 375, 53-63
29. Feldman D., Zhao X. Y., Krishnan A. V. (2000): Vitamin D and prostate cancer. Endocrinology 141, 5-9
30. Frampton R. J., Omond S. A., Eisman J. A. (1983): Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 43, 4443-4447
31. Grant W. B., Garland C. E. (2003): Vitamin D as a risk reduction factor for colorectal cancer. Am. Fam. Physician 67, 465
32. Gross C., Eccleshall T. R., Malloy P. J., Villa M. L., Marcus R., Feldman D. (1996): The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J. Bone Miner. Res. 11, 1850-1855
33. Gross C., Peehl D. M., Feldman D. (1997): Vitamin D and prostate cancer. In: Vitamin D (Eds. D. Feldman, F. H. Glorieux and J. W. Pike), pp. 1125-1139, Academic Press, San Diego
34. Haddad J. G., Matsuoka L. Y., Hollis B. W., Hu Y. Z., Wortsman J. (1993): Human plasma transport of vitamin D after its endogenous synthesis. J. Clin. Invest. 91, 2552-2555
35. Hartwell D., Hassager C., Christiansen C. (1987): Effect of vitamin D2 and vitamin D3 on the serum concentrations of 1,25(OH)2D2, and 1,25(OH)2D3 in normal subjects. Acta Endocrinol. (Copenh) 115, 378-384
36. Haussler M. R., Whitfield G. K., Haussler C. A., Hsieh J. C., Thompson P. D., Selznick S. H., Dominguez C. E., Jurutka P. W. (1998): The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13, 325-349
37. Hellerstedt B. A., Pienta K. J. (2002): The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52, 154-179
38. Holick M. F. (1994): McCollum Award Lecture, 1994: vitamin D - new horizons for the 21st century. Am. J. Clin. Nutr. 60, 619-630
39. Holick M. F. (2003): Vitamin D: A millenium perspective. J. Cell. Biochem. 88, 296-307
40. Hsieh J. C., Shimizu Y., Minoshima S., Shimizu N., Haussler C. A., Jurutka P, W., Chen T. C., Persons K. S., Lu Z., Mathieu J. S., Holick M. F. (1998): An evaluation of the biologic activity and vitamin D receptor binding affinity of the photoisomers of vitamin D3 and previtamin D3. J. Nutr. Biochem. 11, 267-272
41. 2+ exchanger in the heart and brain. Gen. Physiol. Biophys. 23, 417-422
42. Ingles S. A., Coetzee G. A., Ross R. K., Henderson B. E., Kolonel L. N., Crocitto L., Wang W., Haile R. W. (1998): Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 58, 1620-1623
43. Jones G., Strugnell S. A., DeLuca H. F. (1998): Current understanding of the molecular actions of vitamin D. Physiol. Rev. 78, 1193-1231
44. Jurutka P. W., Remus L. S., Whitfield G. K., Thompson P. D., Hsieh J. C., Zitzer H., Tavakkoli P., Galligan M. A., Dang H. T., Haussler C. A., Haussler M. R. (2000): The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol. Endocrinol. 14, 401-420
45. Kemmis C. M., Salvador S. M., Smith K. M., Welsh J. (2006): Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J. Nutr. 136, 887-892
46. Konety B. R., Johnson C. S., Trump D. L., Getzenberg R. H. (1999): Vitamin D in the prevention and treatment of prostate cancer. Semin. Urol. Oncol. 17, 77-84
47. Krill D., DeFlavia P., Dhir R., Luo J., Becich M. J., Lehman E., Getzenberg R. H. (2001): Expression patterns of vitamin D receptor in human prostate. J. Cell. Biochem. 82, 566-572
48. Krishnan A. V., Peehl D. M., Feldman D. (2003): Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J. Cell. Biochem. 88, 363-371
49. Lips P. (2006): Vitamin D physiology. Prog. Biophys. Mol. Biol. 92, 4-8
50. Love-Schimenti C. D., Gibson D. F., Ratnam A. V., Bikle D. D. (1996): Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer Res. 56, 2789-2794
51. Ly L. H., Zhao X. Y., Holloway L., Feldman D. (1999): Liarozole acts synergistically with 1α,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140, 2071-2076
52. Ma J. F., Nonn L., Campbell M. J., Hewison M., Feldman D., Peehl D. M. (2004): Mechanisms of decreased Vitamin D 1α-hydroxylase activity in prostate cancer cells. Mol. Cell. Endocrinol. 221, 67-74
53. Macejová D., Brtko J. (2001): Chemically induced carcinogenesis: a comparison of 1-methyl-1-nitrosourea, 7,12-dimethylbenzanthracene,diethylnitroso-amine and azoxymethan models (Minireview). Endocr. Regul. 35, 53-59
54. Macejová D., Radikova Z., Macho L., Liška J., Brtko J. (2005): MNU-induced carcinogenesis of rat mammary gland: effect of thyroid hormone on expression of retinoic acid receptors in tumours of mammary gland. Mol. Cell. Endocrinol. 244, 47-56
55. MacLaughlin J. A., Anderson R. R., Holick M. F. (1982): Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin. Science 216, 1001-1003
56. Malloy P. J., Feldman D. (1999): Vitamin D resistance. Am. J. Med. 106, 355-370
57. McMichael A. J., Potter J. D. (1980): Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J. Natl. Cancer Inst. 65, 1201-1207
58. Mehta R. G. (2000): Experimental basis for the prevention of breast cancer. Eur. J. Cancer 36, 1275-1282
59. Mezzetti G., Monti M. G., Casolo L. P., Piccinini G., Moruzzi M. S. (1988): 1,25-dihydroxycholecalciferol-dependent calcium uptake by mouse mammary gland in culture. Endocrinology 122, 389-394
60. Miettinen S., Ahonen M. H., Lou Y. R., Manninen T., Tuohimaa P., Syvala H., Ylikomi T. (2004): Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Int. J. Cancer 108, 367-373
61. Miller G. J. (1999): Vitamin D and prostate cancer: biological interactions and clinical potentials. Cancer Metastasis Rev. 17, 353-360
62. Miller G. J., Stapleton G. E., Ferrara J. A., Lucia M. S., Pfister S., Hedlund T. E., Upadhya P. (1992): The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D3. Cancer Res. 52, 515-520
63. Miller G. J., Stapleton G. E., Hedlund T. E., Moffat K. A. (1995): Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1, 997-1003
64. Miyamoto K., Kesterson R. A., Yamamoto H., Taketani Y., Nishiwaki E., Tatsumi S., Inoue Y., Morita K., Takeda E., Pike J. W. (1997): Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol. Endocrinol. 11, 1165-1179
65. Moras D., Gronemeyer H. (1998): The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol. 10, 384-391
66. Napoli J. L., Fivizzani M. A., Schnoes H. K., DeLuca H. F. (1979): Synthesis of vitamin D5: its biological activity relative to vitamins D3 and D2. Arch. Biochem. Biophys. 197, 119-125
67. Nishimura A., Shinki T., Jin C. H., Ohyama Y., Noshiro M., Okuda K., Suda T. (1994): Regulation of messenger ribonucleic acid expression of 1α,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 134, 1794-1799
68. 3 is present in an intestinal caveolae membrane fraction. Biochem. Biophys. Res. Commun. 298, 414-419
69. Ogunkolade B. W., Boucher B. J., Fairclough P. D., Hitman G. A., Dorudi S., Jenkins P. J., Bustin S. A. 2002): Expression of 25-hydroxyvitamin D-1-α-hydroxylase mRNA in individuals with colorectal cancer. Lancet 359, 1831-1832
70. Peehl D. M., Seto E., Hsu J. Y., Feldman D. (2002): Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J. Urol. 168, 1583-1588
71. Pinette K. V., Yee Y. K., Amegadzie D. Y., Nagpal S. (2003): Vitamin D receptor as a drug discovery target. Mini Rev. Med. Chem. 3, 193-204
72. Prufer K., Barsony J. (2002): Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor. Mol. Endocrinol. 16, 1738-1751
73. Reichel H., Koeffler H. P., Norman A. W. (1989): The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320, 980-991
74. Robsahm T. E., Tretli S., Dahlback A., Moan J. (2004): Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control 15, 149-158
75. Rochel N., Wurtz J. M., Mitschler A., Klaholz B., Moras D. (2000): The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell 5, 173-179
76. Rustin G. J., Quinnell T. G., Johnson J., Clarke H., Nelstrop A. E., Bollag W. (1996): Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br. J. Cancer 74, 1479-1481
77. Sakr W. A., Haas G. P., Cassin B. F., Pontes J. E., Crissman J. D. (1993): The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J. Urol. 150, 379-385
78. Saunders D. E., Christensen C., Lawrence W. D., Malviya V. K., Malone J. M., Williams J. R., Deppe G. (1992): Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol. Oncol. 44, 131-136
79. Saunders D. E., Christensen C., Williams J. R., Wappler N. L., Lawrence W. D., Malone J. M., Malviya V. K., Deppe G. (1995): Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs 6, 562-569
80. Sawada N., Sakaki T., Ohta M., Inouye K. (2000): Metabolism of vitamin D3 by human CYP27A1. Biochem. Biophys. Res. Commun. 273, 977-984
81. Shabahang M., Buras R. R., Davoodi F., Schumaker L. M., Nauta R. J., Evans S. R. (1993): 1,25 Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53, 3712-3718
82. Schuster I., Egger H., Nussbaumer P., Kroemer R. T. (2003): Inhibitors of vitamin D hydroxylases: structure-activity relationships. J. Cell. Biochem. 88, 372-380
83. Schuster I., Egger H., Herzig G., Reddy G. S., Schmid J. A., Schussler M., Vorisek G. (2006): Selective inhibitors of vitamin D metabolism - new concepts and perspectives. Anticancer Res. 26, 2653-2668
84. Schwartz G. G., Hulka B. S. (1990): Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10, 1307-1311
85. Schwartz G. G., Whitlatch L. W., Chen T. C., Lokeshwar B. L., Holick M. F. (1998): Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 7, 391-395
86. Skowronski R. J., Peehl D. M., Feldman D. (1993): Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132, 1952-1960
87. Solomon C., Macoritto M., Gao X. L., White J. H., Kremer R. (2001): The unique tryptophan residue of the vitamin D receptor is critical for ligand binding and transcriptional activation. J. Bone Miner. Res. 16, 39-45
88. Sone T., Kerner S., Pike J. W. (1991): Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. J. Biol. Chem. 266, 23296-23305
89. Szpirer J., Szpirer C., Riviere M., Levan G., Marynen P., Cassiman J. J., Wiese R., DeLuca H. F. (1991): The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. Genomics 11, 168-173
90. Tangpricha V., Flanagan J. N., Whitlatch L. W., Tseng C. C., Chen T. C., Holt P. R., Lipkin M. S., Holick M. F. (2001): 25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue. Lancet 357, 1673-1674
91. Tanner M. M., Grenman S., Koul A., Johannsson O., Meltzer P., Pejovic T., Borg A., Isola J. J. (2000): Frequent amplification of chromosomal region 20ql2-ql3 in ovarian cancer. Clin. Cancer Res. 6, 1833-1839
92. Tokar E. J., Webber M. M. (2005): Chemoprevention of prostate cancer by cholecalciferol (vitamin D3): 25-hydroxylase (CYP27A1) in human prostate epithelial cells. Clin. Exp. Metastasis 22, 265-273
93. Trump D. L., Potter D. M., Muindi J., Brufsky A., Johnson C. S. (2006): Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 106, 2136-2142
94. Uitterlinden A. G., van Leeuwen J. P., Pols H. A. (2001): Genetics and genomics of osteoporosis. In: Osteoporosis (Eds. R. Marcus, D. Feldman and J. Kelsey), pp. 639-667, Academic Press, San Diego
95. Van Baal J., Yu A., Hartog A., Fransen J. A., Willems P. H., Lytton J., Bindels R. J. (1996): Localization and regulation by vitamin D of calcium transport proteins in rabbit cortical collecting system. Am. J. Physiol. 271, F985-993
96. Vink-van Wijngaarden T., Pols H. A., Buurman C. J., van den Bemd G. J., Dorssers L. C., Birkenhager J. C., van Leeuwen J. P. (1994): Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res. 54, 5711-5717
97. Wikvall K. (2001): Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (review). Int. J. Mol. Med. 7, 201-209
98. Wu G., Fan R. S., Li W., Ko T. C., Brattain M. G. (1997): Modulation of cell cycle control by vitamin D3 and its analogue, E131089, in human breast cancer cells. Oncogene 15, 1555-1563
99. Yu W. D., McElwain M. C., Modzelewski R. A., Russell D. M., Smith D. C., Trump D. L., Johnson C. S. (1998): Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumour activity with dexamethasone. J. Natl. Cancer Inst. 90, 134-141